Evidence map›Paper›PMID 42501071›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

Yassine Al Tabaa, Clément Bailly, Xavier Palard-Novello, Anne-Ségolène Cottereau, Jérémie Tordo, Pierre Sesques, Guillaume Cartron, Roch Houot, Roberta Di Blasi, Guillaume Manson and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yassine Al Tabaa *Scintidoc Nuclear Medicine Center, 25 Rue de Clémentville, 34070, Montpellier, France.
Clément Bailly *Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.
Xavier Palard-NovelloUniv Rennes, CLCC Eugène Marquis, INSERM, LTSI-UMR 1099, 35000, Rennes, France.
Anne-Ségolène CottereauDepartment of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Jérémie TordoRadiantys Nuclear Medicine Center, Villeurbanne, France.
Pierre SesquesDepartment of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Guillaume CartronService d'Hématologie, CHU Montpellier, UMR-CNRS 5553, Université Montpellier, Montpellier, France.
Roch HouotDepartment of Hematology, University Hospital of Rennes, Rennes, France.
Roberta Di BlasiAssistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-Oncologie, Paris, France.
Guillaume MansonDepartment of Hematology, University Hospital of Rennes, Rennes, France.
Bastien LesneDépartment de Biostatistiques, LYSARC, Lyon, France.
Loïc YsebaertDépartment d'Hématologie, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Salim KanounPixilib SAS, Toulouse, France.
Emelie Van ZeleLYSA-IM, Créteil, France.
Steven Le GouillInstitut Curie, Paris, France.
Benoît TessoulinNantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.
Caroline Bodet-MilinNantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.
Françoise Kraeber-BodéréNantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.
Laetitia VercellinoDepartment of Nuclear Medicine, Saint-Louis Hospital, AP-HP, INSERM UMR_S942, Université Paris Cité, Paris, France. laetitia.vercellino@aphp.fr.ORCID http://orcid.org/0000-0003-0235-2942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCAR T-cell therapy has changed the management of relapsed/refractory (R/R) Diffuse large B-cell lymphoma (DLBCL). Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (PET/CT) plays a central role in lymphoma response assessment, but its prognostic use remains insufficiently standardized in this setting.

methodsPatients from the French DESCAR-T registry treated in third line or beyond with commercial anti-CD19 CAR T-cells in real-life, and having centrally reviewed PET/CT before infusion, and at one month (M1) or three months (M3) post-infusion were included. For each visit, Total Metabolic Tumor Volume (TMTV) and SUVmax were measured. Deauville score (DS) and response according to 2014 Lugano classification were registered on follow-up PET/CT. Optimal TMTV cut-offs at baseline, M1 and M3 follow-up for progression-free survival (PFS) and overall survival (OS) and the prognostic impact of DS at M1 and M3 were determined.

resultsA total of 212 R/R DLBCL patients were analysed. Baseline median SUVmax was 16.4 and median TMTV 41.3 cm3. A baseline TMTV cut-off of 30 cm

conclusionBaseline TMTV and metabolic response assessed by DS, together with residual TMTV on follow-up PET/CT, are strong prognostic biomarkers in R/R DLBCL patients treated with anti-CD19 CAR T-cells.

Indexed as

Fluorodeoxyglucose F18Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRecurrenceReference StandardsTreatment OutcomeFluorodeoxyglucose F18CAR T-cellsDiffuse large B-cell lymphomaFDG PETMetabolic tumour volumeTherapeutic evaluation

Identifiers

PMID42501071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.